Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
5-hydroxymethylation Signatures in Plasma Circulating Cell-free DNA as Markers for Tumor Burden and Recurrence in Appendiceal and Colorectal Peritoneal Metastasis
Sponsor: University of Chicago
This observational or N/A phase trial investigates Appendix Cancer and Colorectal Cancer Metastatic and is currently ongoing. University of Chicago leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting
-
Apr 2025 — Jan 2026 [monthly]
Active Not Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Dec 2021 — Mar 2024 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Dec 2019 — Nov 2020 [monthly]
Recruiting
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .